加入收藏 | 设为首页 | 联系我们

产品搜索

相关文章

联系我们

联系人:蒋经理
电话:86-25-86880024
号码:86-25-86880024
手机:18066071954
地址:南京市雨花区长虹路222号
Email: duhaitao@cobioer.com

产品展示 / PRODUCTS
药靶细胞株 > kinase激酶细胞株 > CBP73190BCR-ABL1 T315I/BaF3

BCR-ABL1 T315I/BaF3
名称 BCR-ABL1 T315I/BaF3
型号 CBP73190
报价
特点 BCR-ABL1 [T315I]/BaF3,母细胞:BaF3,冻存条件:90% FBS+10% DMSO;ABL1 是一种酪氨酸激酶,在正常细胞中,它在细胞分化和细胞周期调节中发挥作用。 BCR-ABL1 融合基因产生一种组成型活性酪氨酸激酶,导致不受控制的增殖。
  • 详细内容

BCR-ABL1 [T315I]/BaF3

CBP73190

I. Introduction

Cell Line Name:

BCR-ABL1 [T315I]/BaF3

Host Cell:

Ba/F3

Stability:16 passages

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10% FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative


II.Background

Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes.
ABL1 is a tyrosine kinase, and, in normal cells, it plays a role in cellular differentiation and regulation of the cell cycle. The BCR-ABL1 fusion gene creates a constitutively active tyrosine kinase, which leads to uncontrolled proliferation.
Imatinib is the first-generation ABL tyrosine kinase inhibitor, and it was approved by the FDA in 2001; label indications for CML include use in newly diagnosed adult and pediatric patients and in patients after failure of interferon-alpha therapy. While treatment responses to imatinib are often dramatic and lasting, 30–40% of patients will eventually need further treatment (Santos et al. 2011). In many but not all cases, this is due to the acquisition of point mutations in the tyrosine kinase domain of the BCR-ABL1 fusion gene, which renders the protein insensitive to the inhibitory effect of imatinib. This type of disease progression led to the development of second-line TKIs: dasatinib, nilotinib, and bosutinib. Dasatinib and bosutinib have the additional advantage of being inhibitors of SRC.
The second-generation TKIs, dasatinib, nilotinib, and bosutinib, are more potent than imatinib, and they were developed to treat cases of CML resistant to imatinib. Dasatinib and nilotinib are approved for use in CML in newly diagnosed adults, while dasatinib, nilotinib, and bosutinib are approved for use in adults with resistance or intolerance to prior therapy that included imatinib (FDA 2012). Soverini et al. (2011) made mutation-specific treatment decision recommendations that were adopted by NCCN (2012). Recommendations based on preclinical data are as follows: for T315I, HSCT or clinical trial; for V299L, T315A, and F317L/V/I/C, consider nilotinib rather than dasatinib; for Y253H, E255K/V, and F359V/C/I, consider dasatinib rather than nilotinib; and for all other mutations, consider high-dose imatinib, dasatinib, or nilotinib.
Ponatinib is a third-line TKI, developed specifically to address imatinib resistance due to the BCR-ABL1 T315I resistance mutation. Ponatinib is currently being investigated in phase III clinical trials.


III. Representative Data

1. WB of BCR-ABL1 expression

CBP73190 WB.jpg

2. Anti-proliferation assay

CBP7190 fig.png

Figure 2. CTG Proliferation Assay of BaF3 BCR-ABL1 T315I Cells.


如果你对CBP73190BCR-ABL1 T315I/BaF3感兴趣,想了解更详细的产品信息,填写下表直接与厂家联系:


留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
QQ在线客服
电话咨询
  • 25-86880024
  • 手机:18066071954

化工仪器网

推荐收藏该企业网站
扫一扫访问手机站扫一扫访问手机站
访问手机站